André Frenzel studied biology at Johannes Gutenberg University Mainz and received his PhD from the Leibniz Universität in Hannover.
In 13 years in the antibody field, André published more than 30 articles (including book chapters and reviews) on discovery and development of human antibodies and antibody phage display.
He works on the development of human and human-like antibodies for diagnostics and therapy with a focus on cancer and so-called difficult targets.
In 2009 he joined the working group of Prof. Dübel at University Braunschweig.
André is co-founder of YUMAB and acts as CSO for the company.